This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 24, 2006
Last updated: May 15, 2017
Last verified: May 2017
The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles (2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m^2).

Condition Intervention Phase
Glioma Astrocytoma Oligodendroglioma Glioblastoma Drug: Temozolomide Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression. [ Time Frame: 6 months ]
    Progression-free survival as determined by Kaplan-Meier method.

Enrollment: 120
Actual Study Start Date: June 9, 2006
Study Completion Date: September 15, 2009
Primary Completion Date: September 15, 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Temozolomide
Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
Drug: Temozolomide
Subjects will receive temozolomide 50 mg/m^2 for cycles of 28 days for 12 months or until progression
Other Name: SCH 52365


Ages Eligible for Study:   19 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, greater than 18 years old.
  • Surgically confirmed diagnosis of malignant glioma, specifically anaplastic glioma (anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO], anaplastic oligoastrocytoma [AOA]) or glioblastoma multiforme (GBM).
  • Must have completed at least 2 cycles (2 months) of conventional 5/28 temozolomide, with radiological evidence of progression.
  • GBM treated with concurrent chemoradiation with temozolomide according to the EORTC/NCIC (European Organization for Research & Treatment of Cancer/National Cancer Institute of Canada) protocol.
  • Evidence of progression confirmed radiologically (CT [computed tomography] or MRI [magnetic resonance imaging]).
  • Patients must be enrolled within 2 weeks of last radiological confirmation of progression, except for patients undergoing surgical resection.
  • Patients undergoing surgical resection for recurrent disease must be enrolled within 2 weeks of the post-surgical scan.
  • Patients with no residual disease after surgery are allowed.
  • Steroids dose should have been stabilized during the last 2 weeks prior to enrollment.
  • Use of medically approved contraception in fertile males and females.
  • Women of childbearing potential must have a negative urine or serum pregnancy test (urinary excretion or serum level of bHCG [beta human chorionic gonadotropin]) within 24 hours of inclusion in the study.
  • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
  • Signed informed consent form.

Exclusion Criteria:

  • GBM progression during the first 2 months of adjuvant temozolomide (5/28).
  • AA progression during the first 2 months of standard temozolomide therapy (5/28).
  • Chemotherapy for the malignant glioma other than temozolomide.
  • More than one prior course of chemotherapy with temozolomide.
  • Patient evolving from anaplastic glioma to GBM following primary therapy.
  • Patient older than 70 years or who received no conventional chemoradiation regimen.
  • Patient who received radiotherapy for recurrent disease.
  • Patient with metastatic disease.
  • Known human immunodeficiency virus (HIV) infection.
  • History of non-compliance to other therapies.
  • Inadequate hematological, renal and hepatic function according to all of the following laboratory values (to be performed within 14 days, inclusive, prior to study inclusion):
  • Absolute neutrophil count <=1.5 ×10^9/L;
  • Platelets <=100 ×10^9/L;
  • Hemoglobin <90 g/L;
  • Serum creatinine >=1.5 times upper limit of laboratory normal (ULN);
  • Total serum bilirubin >=1.5 times ULN;
  • ASAT (AST [aspartate aminotransferase]) or ALAT (ALT [alanine aminotransferase) >2.0 times ULN;
  • Alkaline phosphatase of >2.5 times ULN.
  • Known chronic hepatitis B or hepatitis C infection.
  • Any other serious medical condition, according to the medical judgment of the physician prior to inclusion in the study.
  • Any medical condition that could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction).
  • Other malignancies during the previous 5 years with the exception of surgically cured carcinoma in-situ of the cervix and basal cell carcinoma or non-melanoma skin cancer.
  • Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule as discussed with the patient before inclusion in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00392171     History of Changes
Other Study ID Numbers: P04601
Study First Received: October 24, 2006
Results First Received: April 21, 2010
Last Updated: May 15, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description:

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on June 22, 2017